<DOC>
	<DOCNO>NCT00479258</DOCNO>
	<brief_summary>To assess safety efficacy Exubera pulmonary function glycemic control subject age 6-17 1 year period .</brief_summary>
	<brief_title>Safety And Efficacy Of Exubera Compared With Subcutaneous Human Insulin Therapy In Children And Adolescents</brief_title>
	<detailed_description>Pfizer announce October 2007 would stop marketing Exubera . At time recruitment pediatric study , A2171083 , place hold . Two subject complete informed consent/assent process enter A2171083 study none receive treatment . The first subject withdrew consent Baseline Run-in period prior Randomization . The second subject screen fail Visit 1 . After time , Nektar , company Pfizer license Exubera , announce April 9 , 2008 stop search new marketing partner . Accordingly , commercial availability Exubera . As result , study A2171083 terminate recruitment take place .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Subjects Type 1 diabetes mellitus 6 month . Males female age 6 17 year . Subjects receive , able tolerate , minimum 3 unit pre prandial dose short act subcutaneous insulin . Subjects use insulin pump Smoking</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>October 2008</verification_date>
</DOC>